Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Magdalen College Chapel was lit up in the colours of Rare Disease Day last week, as part of the global Chain of Lights initiative.

For the third consecutive year, the signature green, pink, teal and purple colours of the Rare Disease Day movement were projected across the college chapel façade on Oxford’s High Street in a powerful display organised by the Oxford-Harrington Rare Disease Centre (OHC), demonstrating their solidarity with the 500 million people worldwide living with rare diseases.

Observed annually on 28 February (or 29 February in leap years—the rarest day of the year), Rare Disease Day is a globally coordinated movement dedicated to achieving equity in social opportunities, healthcare, diagnosis and access to therapies. Since its launch in 2008, it has united a diverse international community around the shared goal of improving the lives of those affected by rare conditions.

The Oxford-Harrington Rare Disease Centre, based within the Department of Paediatrics, is a pioneering transatlantic partnership between the University of Oxford and the Harrington Discovery Institute at University Hospitals in Cleveland, US. By connecting world-class academic science with drug development and industry expertise, the OHC works to translate breakthrough discoveries into life-changing therapies and cures for rare diseases worldwide.

A disease is defined as rare when it affects fewer than 1 in 2,000 people. In the UK alone, more than 3.5 million people live with a rare condition. These disorders are often complex, with symptoms that vary widely between diseases and individuals, and many currently have no effective cures—placing a profound burden on patients and families.

Across the Atlantic, Terminal Tower in Cleveland was also illuminated in Rare Disease Day colours.

Similar stories

New clinical trials begin in Burkina Faso

Vaccinations have started at the Institut de Recherche en Sciences de la Santé – Clinical Research Unit of Nanoro (IRSS-URCN), Burkina Faso for two clinical trials to assess the blood-stage malaria vaccine candidates R78C and RH5.1 with Matrix-M (developed by the Draper Lab in the Department of Paediatrics), in combination with the R21/​Matrix-M vaccine, which targets the earlier liver-stage. The trials are sponsored by the University of Oxford (UOXF), UK, with the European Vaccine Initiative (EVI) acting as both a co-funder and collaborator. These exciting studies are expected to provide proof-of-concept for the use of a multi-stage vaccine to extend the protection against malaria and help lead to future efforts to eliminate it by targeting two stages of the parasite’s life-cycle.